Impact of prolonged use of adjuvant tocolytics after cervical cerclage on late abortion and premature delivery

Figures & data

Figure 1. Flow diagram on participants flow in the study.

Table 1. Clinical and demographic data of the patients.

Variable
Maternal age	31.54 ± 4.54(23–44)
Gestation at cerclage (weeks)	19.49 ± 4.70(12–27)
Primipara (%)	56.90% (33/58)
Multipara (%)	43.10% (25/58)
Singleton pregnancies (%)	84.48% (49/58)
Bigeminal or multiple pregnancies (%)	15.52% (9/58)
Cervical dilatation
<1 cm (%)	18.97% (11/58)
≥1 cm and <2 cm (%)	62.07% (36/58)
≥2 cm and <4 cm (%)	15.52% (9/58)
≥4 cm (%)	3.44% (2/58)
Cervical length
2 cm (%)	3.44% (2/58)
≤2 cm and >1 cm (%)	25.86% (15/58)
≤1 cm (%)	70.70% (41/58)

Table 2. Pregnancy outcomes.

	Mean ± Standard/rate
Successful pregnancy (%)	74.14% (43/58)
Delivery gestational age (weeks)	35.91 ± 5.16
<28 weeks (%)	12.07% (7/58)
28–33^+6weeks (%)	10.34% (6/58)
34–37 weeks (%)	8.62% (5/58)
>37 weeks (%)	68.97% (40/58)
Prolonged gestational age (weeks)	16.42 ± 7.84
Duration of medication (days)	15.34 ± 13.16
Survival (%)	93.10% (54/58)

Table 3. Correlation of prolonged gestational age with longest time of medication.

		Longest time of medication	Gestational deliver age
Prolonged gestational age	Correlation of Pearson	−0.453**	0.816**

**p-Value <.01.

Data availability statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.